TG Therapeutics (NASDAQ: TGTX) reported Q3 EPS of ($0.26), $0.12 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $2.03 million versus the consensus estimate of $1.46 million.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.